期刊名称：JOURNAL OF GYNECOLOGIC ONCOLOGY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Journal of Gynecologic Oncology (JGO) is an international peer-reviewed periodical journal on recent developments in the management of female reproductive tract cancers.
JGO’s goal is to publish the highest quality manuscripts dedicated to the advancement of the care of patients with gynecologic cancer. Research areas covered by this journal include: epidemiology, treatment strategies such as surgery, chemotherapy, radiotherapy, or combination therapy, quality of life issues, and basic researches comprising genetics, immunology, and translational research.
This journal publishes original articles on both clinical and basic researches, reviews, and meeting reports, encompassing the whole topics of gynecologic oncology. It is published four times a year in March, June, September and December.
Journal of Gynecologic Oncology (JGO) is the official journal of the Korean Society of Gynecologic Oncology and Colposcopy (KSGOC).
Instructions to Authors
|
The Journal of Gynecologic Oncology (JGO), the official journal of the Korean Society of Gynecologic Oncology and Colposcopy, publishes the highest quality manuscripts dedicated to gynecologic oncology. Published four times per year in March, June, September and December, the journal aims at publishing evidence-based, scientifically written articles, including original articles, review articles, case reports, and selected editorials.
JGO has on online submission and peer review system. Manuscripts should be submitted online at http://mc.manuscriptcentral. com/jgo. Authors may submit manuscripts and tract their progress to final decision
Authors who are unable to submit online should contact the Editorial Office:
Korean Society of Gynecologic Oncology and Colposcopy
102-Ho, 55-5, Nonhyeon-dong, Gangnam-gu, Seoul 135-010, Republic of Korea
 Tel: +82-2-512-5915
Fax: +82-2-512-5421
E-mail: gyncancer@gyncancer.or.kr |
 |
| Original articles are papers containing results of basic and clinical investigations, which are sufficiently well documented to be acceptable to critical readers. Maximum length of manuscript is 3500 words of body text, excluding the abstract, references, figures, and tables. These articles are limited to 40 references. |
| Review articles are usually solicited by the Editor-in-Chief and describe concise review on subjects of importance to medical researchers. Authors who wish to submit an unsolicited review should contact the Editor-in- Chief to determine the appropriateness of their review for publication in JGO. These articles are limited to 4500 words of body text, excluding the abstract, references, figures, and tables. The Editors also suggest a limit of 150 references. |
| Case reports as well as brief communications describe up to three cases of a particular condition that is unusual and also provides new insights into diagnosis or clinical management. Maximum length of manuscript is 1500 words, 10 references, and a total 4 images (up to four published pages). |
| Correspondence (letters to the Editor) may be in response to a published article, or a short, free-standing piece expressing an opinion. If the Correspondence is in response to a published article, the Editor- in-Chief may choose to invite the article’s authors to write a Correspondence reply. Correspondence should be no longer than two pages in length. |
| Editorial is an invited perspective in gynecologic oncology, dealing on very active areas of research, fresh insights and debates. |
 |
Authorship
In accordance with the ICMJE, each author should have participated sufficiently in the work to take public responsibility for the content. All other contributors who do not meet sufficient criteria for authorship should be noted in the Acknowledgments section. The number of authors listed on the manuscript should not exceed seven for regular articles (except in the case of cooperative group or multi-center trials); five for Review Articles or Case Reports; and three for Correspondence. |
Conflict of interest
All contributors to JGO are required to disclose financial and other relationships with entities that have investment, licensing, or other commercial interests in the subject matter under consideration in their article. These disclosures should include, but are not limited to, relationships with pharmaceutical and biotechnology companies, device manufacturers, or other commercial entities whose products or services are related to the subject matter of the submission. |
Ethics
For clinical trials, details of ethical committee approval and the type of informed consent should be stated. Patients�and volunteers�names, initials, and hospital numbers should not be used. We endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving human materials have been performed in accordance with these principles. For animal experiments, “the Guiding Principles in the Care and Use of Animals�approved by the American Physiological Society have to be observed. |
Copyright and permissions
Upon acceptance of an article, authors will be asked to transfer copyright. This transfer will ensure the widest possible dissemination of information. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. |
Evidence-based medicine
JGO has incorporated specific guidelines for reporting randomized controlled trials (ie, CONSORT), meta-analyses and systematic reviews of randomized controlled trials (ie, PRISMA), meta-analyses and systematic reviews of observational studies (ie, MOOSE), observational studies (ie, STROBE), and studies of diagnostic accuracy (ie, STARD). In your cover letter, be sure to indicate that you have followed the CONSORT, PRISMA, MOOSE, STROBE or STARD guidelines, as appropriate. The checklists and guidelines are available on our web site (www.ejgo.org). |
Clinical trial registration
JGO has endorsed the statement from the ICMJE that all clinical trials must be enrolled in a central registry in order to be considered for publication. This requirement will lessen the chance of publication bias by making all trials (published or unpublished) available to clinicians, investigators, and the public, even those that are negative or reflect unfavorably on a research sponsor’s product.
For the policies on the research and publication ethics not stated in this instructions, ‘Good Publication Practice Guidelines for Medical Journals (http://kamje.or.kr/publishing_ethics.html)� or ‘Guidelines on good publication (http://www.publicationethics.org.uk/guideline)�can be applied. |
 |
| JGO will consider manuscripts prepared in accordance with the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals.�/TD> |
Title Page
The first page of the manuscript must contain the following information: (1) succinct title of the report; (2) author list of 20 or fewer names; (3) names of each author’s institutions and an indication of each author’s affiliation; (4) acknowledgements of research support; (5) name, address, telephone and fax numbers, and e-mail address of the corresponding author; (6) running head of fewer than 65 characters (including spaces); (7) list of where and when the study has been presented in part elsewhere, if applicable; and (8) disclaimers, if any. |
Abstract
Abstracts are limited to 250 words and must appear after the title page. Abstracts must be formatted according to the following headings: (1) Objective, (2) Patients and Methods (or Materials and Methods, Methods, or similar headings), (3) Results, and (4) Conclusion. A non-structured abstract is applied to case reports. Abstract is not required for editorials or for correspondence. At the bottom of abstract page, up to six keywords should be listed to be used as index terms. For the selection of keywords, refer to Medical Subject Heading (MeSH) in Index Medicus. |
Text
Organize the manuscript into four main headings: (1) Introduction, (2) Materials and Methods, (3) Results, and (4) Discussion. Other descriptive headings and subheadings may be used if appropriate. The body of manuscript should be written as concisely as possible and must not exceed the manuscript category word limits described herein. All pages of a submission should be numbered and double spaced with a margin of 2.5 cm (1 inch) on every side. Arial and Times New Roman at 10 pt size are recommended fonts for all text. |
| Introduction should orient the reader to the purposes of the study and should be as concise as possible, without subheadings. |
| Materials and Methods should be sufficiently detailed to enable the experiments to be reproduced. Appropriate IRB or IACUC approval for the research should be obtained. Also, the statistical analysis and software programs used should be described. As for case reports, Case Report section comprising case history or case description replaces the Materials and Methods section as well as Results section. |
| Results should present detailed description of the findings in the text and/or tables and figures. But, excessive repetition of tables and figure contents should be avoided. |
| Discussion should appraise implications of the findings and place them in the context of prior reports. Speculation is permitted, but it must be supported by the presented data of authors and be well founded. |
Conflict of interest
Under a subheading “Conflict of Interest statement,�all authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence their work. |
Acknowledgments
All persons who have made substantial contribution, but who are not eligible as authors are named in acknowledgment. |
References
References must be listed and numbered after the body text in the order in which they are cited in the text. Published manuscripts and manuscripts that have been accepted and are pending publications (in press) should be cited in the reference list. When a reference is an abstract or supplement, it must be identified as such in parentheses at the end of the reference. When a reference is unpublished data, a manuscript in preparation, or a manuscript submitted but not in press, it should be included in parentheses in the body of the text, and not cited in the reference list.
Abbreviations of medical periodicals should conform to those used in the latest edition of Index Medicus and on MEDLINE. The “List of Journals Indexed in Index Medicus�includes the latest abbreviations. List all authors up to six. If more than six, list the first six and add “et al.�/TD> |
| Reference Style |
| â—?Journal articles with more than six authors |
| Jeon WJ, Moon EJ, Ryu SY, Kim JJ, Lee KS, Kim SJ, et al. Clinicopathologic characteristics and prognosis of endometrial cancer: a study of 100 cases. Korean J Obstet Gynecol 1994; 37: 1821-8. |
| â—?Book with a single author |
| Hay R. Atlas of human tumor cell lines. San Diego: Academic Press; 1994. |
| â—?Chapter in a multiauthored book with editors |
| Disaia PJ, Creasman WT. The adnexal mass and early ovarian cancer. In: Disaia PJ, Creaseman WT, editors. Clinical gynecologic oncology. 5th ed. St.Louis: Mosby-Year Book; 1997. p.253-61. |
| â—?Conference/meeting presentation |
| Morrow GR, Ryan JL, Kohli S. Modafinil for persistent post-treatment fatigue: An open label study of 82 women with breast cancer. MASCC international symposia 2006, Abstract 11-070. |
| â—?Internet resource |
| AMA: helping doctors help patients [Internet]. Chicago: American Medical Association; c1995-2007 [cited 2007 Feb 22]. Available from: http://www.ama-assn.org/. |
Tables
Tables must be cited in the order in which they appear in the text using Arabic numerals. The table’s legend may include any pertinent notes and must include definitions of all abbreviations and acronyms that have been used in the table. Tables submitted with multiple parts will be renumbered. |
Figures
Figures must be cited in the order they appear in the text using Arabic numerals. Figure legends should appear within the document in a separate section just before the references. Figure legends are required for all article types. All relevant and explanatory information extraneous to the actual figure, including figure part labels, footnotes, abbreviations, acronyms, arrows, and levels of magnification in insets, should be defined in the legend text. Figure legends must not exceed 55 words per figure. Formats accepted on first submission are .eps, .gif, .tiff, .jpeg, and PowerPoint. Photographs (radiographs, CT/MRI scans, and scanned images) must have a resolution of at least 300 dpi. Figure parts should not have figure numbers or letters embedded in the photographs. Labels may be placed on top of the image or set outside of each part. |
 |
| JGO has on online submission and peer review system. Manuscripts should be submitted online at http://mc.manuscriptcentral. com/jgo. Authors may submit manuscripts and tract their progress to final decision. |
Formatting
To facilitate the review process, manuscripts must be in Microsoft Word format (.doc). Do not reveal your identity anywhere in the document. |
Submitting
Log on to http://mc.manuscriptcentral.com/jgo. At the initial screen, click on “Submit a Manuscript� And then, click “New Submissions�link to submit a new manuscript and follow steps 1-5.
Step 1. Manuscript Type, Title and Abstract
Select manuscript type, and enter your title and abstract into the appropriate boxes.
Step 2. Authors and Institutions
Enter your co-authors�information in the boxes under “Add a New Author,�then click “Add to My Authors.�
Step 3. File upload
The manuscript file should not include author’s name or name of organization where the author works. Upload and select the correct file designation for each. All images should be inserted into a PowerPoint file. Acceptable file formats are pdf, doc, and ppt, and each files should not be any bigger than 10 MB in size.
Step 4. Preview
Review the information in the Preview chart for correctness; make changes as needed.
Step 5. Submit |
Editorial and Peer Review Process
The editor selects peer referees by recommendation of the Editorial Board members or from the specialist database owned by the Editorial Board.
Acceptance of the manuscript is decided, based on the critiques and recommended decision of the referees. A referee’s decision is made as “acceptance without revision� “acceptance after minor revision� “review after revision�and “rejection.�If there is marked discrepancy in the decisions between two referees or in opinions between the author and referee(s), the Editor may send the manuscript to another referee for additional comments and recommended decision. Three repeated decisions of “review after revision�are regarded as “rejection.�The reviewed manuscripts are returned back to the corresponding author with comments and recommended revisions. A final decision on acceptance or rejection for publication is forwarded to the corresponding author from the Editorial Office.
The peer review process takes usually four to eight weeks after the manuscript submission.
Revisions are usually requested to take account of criticism and comments made by referees. Failure to resubmit the revised manuscript within two months is regarded as a withdrawal. The corresponding author must indicate clearly what alterations have been made in response to the referees�comments point by point. Acceptable reasons should be given for noncompliance with any recommendation of the referees. |
Editorial Board
| Hee-Sug Ryu, MD, PhD, Ajou University, Suwon, Korea |
|
| Jae Weon Kim, MD, PhD, Seoul National University, Seoul, Korea |
|
| Ki-Hong Chang, MD, PhD, Ajou University, Suwon, Korea |
|
| Chi-Hum Cho, MD, PhD, Keimyung University, Daegu, Korea |
|
| Byung-Ho Nam, PhD, National Cancer Center, Goyang, Korea |
|
| Mi-Kyung Kim, MD, Seoul National University Hospital, Seoul, Korea |
|
Mohamad Farid Aziz, MD, PhD
University of Indonesia, Jakarta, Indonesia
Robert Burger, MD
Fox Chase Cancer Center, Philadelphia, USA
Zeyi Cao, MD
Tsinghua University, Beijing, China
Yin Nin Chia, MD
Kandang Kerbau Women's and Children's Hospital, Singapore Uma Devi, MD
Kidwai Memorial Institute of Oncology, Bangalore, India
Efren Domingo, MD, PhD
University of the Philippines, Manila, Philippines
Jeffrey Fowler, MD
Ohio State University, Columbus, USA
Toshiharu Kamura, MD, PhD
Kurume University, Kurume, Japan
Soon-Beom Kang, MD, PhD
Seoul National University, Seoul, Korea
Byoung Gie Kim, MD, PhD
Sungkyunkwan University, Seoul, Korea
Jong-Hyeok Kim, MD, PhD
University of Ulsan, Seoul, Korea
Seok-Mo Kim, MD, PhD
Chonnam National University, Hwasun, Korea
Seung-Cheol Kim, MD, PhD
Ewha Womans University, Seoul, Korea
Young-Tae Kim, MD, PhD
Yonsei University, Seoul, Korea
Henry Kitchener, MD
University of Manchester, Manchester, UK
Ikuo Konishi, MD, PhD
Kyoto University, Kyoto, Japan
Jong-Min Lee, MD, PhD
Kyung Hee University, Seoul, Korea
Joo-Hyun Nam, MD, PhD
University of Ulsan, Seoul, Korea
Hextan Ngan, MD
University of Hong Kong, Hong Kong, China
Kazunori Ochiai, MD, PhD
Jikei University, Tokyo, Japan
Sang Yoon Park, MD, PhD
National Cancer Center, Goyang, Korea
Jeffrey Tan, MD
Royal Women’s Hospital, Melbourne, Australia
Edward Trimble, MD
National Cancer Institute, Bethesda, USA
Kung-Liahng Wang, MD
Mahidol University, Bangkok, Thailand
Sarikapan Wilailak, MD
Mahidol University, Bangkok, Thailand |
|
| Hye-Min Cho, MA |
|
刊名字顺( Alphabetical List of Journals):
返回页首 